DRUG · Mapped RxNorm record
lapatinib ditosylate
Normalized identity: lapatinib ditosylateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
NCT00499681
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
letrozole
Normalized identity: letrozoleView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
lapatinib ditosylateDRUG · verified · RxNorm: lapatinib ditosylate
letrozoleDRUG · verified · RxNorm: letrozole
placeboOTHER
Sponsors & collaborators
Vanderbilt-Ingram Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00499681 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.